- Home
- CRVS vs SRG Comparison
CRVS vs SRG Comparison
Compare CRVS & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- SRG
- Stock Information
- Founded
- CRVS 2014
- SRG 2014
- Country
- CRVS United States
- SRG United States
- Employees
- CRVS N/A
- SRG N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- CRVS Health Care
- SRG Real Estate
- Exchange
- CRVS Nasdaq
- SRG Nasdaq
- Market Cap
- CRVS 257.0M
- SRG 218.9M
- IPO Year
- CRVS 2016
- SRG 2015
- Fundamental
- Price
- CRVS $3.21
- SRG $3.04
- Analyst Decision
- CRVS Strong Buy
- SRG
- Analyst Count
- CRVS 5
- SRG 0
- Target Price
- CRVS $12.63
- SRG N/A
- AVG Volume (30 Days)
- CRVS 704.3K
- SRG 165.9K
- Earning Date
- CRVS 05-05-2025
- SRG 05-09-2025
- Dividend Yield
- CRVS N/A
- SRG N/A
- EPS Growth
- CRVS N/A
- SRG N/A
- EPS
- CRVS N/A
- SRG N/A
- Revenue
- CRVS N/A
- SRG $17,622,000.00
- Revenue This Year
- CRVS N/A
- SRG N/A
- Revenue Next Year
- CRVS N/A
- SRG N/A
- P/E Ratio
- CRVS N/A
- SRG N/A
- Revenue Growth
- CRVS N/A
- SRG N/A
- 52 Week Low
- CRVS $1.30
- SRG $2.91
- 52 Week High
- CRVS $10.00
- SRG $9.87
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- SRG 29.74
- Support Level
- CRVS $3.06
- SRG $3.27
- Resistance Level
- CRVS $3.45
- SRG $3.40
- Average True Range (ATR)
- CRVS 0.37
- SRG 0.14
- MACD
- CRVS -0.10
- SRG -0.03
- Stochastic Oscillator
- CRVS 8.77
- SRG 6.97
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.